Mammary Cell News Volume 3.48 | Dec 8 2011

VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging α4β1-Positive Osteoclast Progenitors
Here, scientists characterize a bone metastasis dormancy model to show that aberrant expression of vascular cell adhesion molecule 1 (VCAM-1), in part dependent on the activity of the NF-κB pathway, promotes the transition from indolent micrometastasis to overt metastasis. [Cancer Cell] Abstract

Global DNA Hypomethylation Coupled to Repressive Chromatin Domain Formation and Gene Silencing in Breast Cancer
Here, researchers describe complete methylome maps at single nucleotide resolution of a low-passage breast cancer cell line and primary human mammary epithelial cells. [Genome Res] Abstract

Genetic Variants in Oxidative Stress-Related Genes Predict Chemoresistance in Primary Breast Cancer: A Prospective Observational Study and Validation
Investigators hypothesized that polymorphisms in oxidative stress-related genes, including estrogen-quinone metabolizing enzymes NQO2 and GSTM1-5, may influence disease progression and treatment response. [Cancer Res] Abstract

Modeling Invasive Breast Cancer: Growth Factors Propel Progression of HER2-Positive Premalignant Lesions
The integration of a three-dimensional cellular model and clinical data attributes progression of human epidermal growth factor receptor 2 (HER2)-overexpressing lesions to epidermal growth factor (EGF)-like growth factors acting in the context of the tumor’s microenvironment. [Oncogene] Abstract

Opposing Effects of Runx2 and Estradiol on Breast Cancer Cell Proliferation: In Vitro Identification of Reciprocally-Regulated Gene Signature Related to Clinical Letrozole Responsiveness
The purpose of this study is to assess the clinical significance of the interaction between estrogen and Runx2 signaling, previously demonstrated in vitro. [Clin Cancer Res] Abstract

MicroRNA-200c Represses Migration and Invasion of Breast Cancer Cells by Targeting Actin-Regulatory Proteins FHOD1 and PPM1F
Here, researchers demonstrated that modulation of microRNA-200c in breast cancer cells regulates cell migration, cell elongation and TGF-β-induced stress fiber formation, by impacting the re-organization of cytoskeleton that is independent of the ZEB/E-Cadherin-axis. [Mol Cell Biol] Abstract

Hyperactivation of Oxidative Mitochondrial Metabolism in Epithelial Cancer Cells In Situ: Visualizing the Therapeutic Effects of Metformin in Tumor Tissue
Data provides the first functional in vivo evidence that epithelial cancer cells perform enhanced mitochondrial oxidative phosphorylation, allowing them to produce high amounts of ATP. [Cell Cycle] Abstract | Press Release

Aquaporin-5: A Marker Protein for Proliferation and Migration of Human Breast Cancer Cells
Investigators aimed to examine the potential role of aquaporin 5 in the progression of human breast cancer cells. [PLoS One] Abstract

CD44 Promotes Epithelial Mammary Gland Development and Exhibits Altered Localization During Cancer Progression
To better understand the normal function of CD44, scientists have investigated its role in mouse mammary gland development and its expression in human breast and prostate cancer. [Genes Cancer] Abstract

CLINICAL RESEARCH

Breast Cancer Prognosis in BRCA1 and BRCA2 Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study
The purpose of this study is to compare breast cancer prognosis in BRCA1 and BRCA2 mutation carriers with that in patients with sporadic disease. [ J Clin Oncol] Abstract

Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the American Society of Clinical Oncology and College of American Pathologists HER2-Positivity Criteria
Using data from the HER2-positive breast cancer adjuvant trial N9831, investigators compared eligibility for patients who met both criteria, and disease-free survival was assessed by Cox proportional hazards regression. [J Natl Cancer Inst] Abstract

Novel Approach to Treating Breast Cancer Shows Great Promise
In a novel therapeutic approach to treating breast cancer, researchers are reporting positive results from a clinical trial of a drug that targets tumor stem cells. [Press release from EurekAlert! discussing research presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio] Press Release

Molecular Differences May Be Used to Predict Early vs. Late Hormone Receptor-Positive Breast Cancer Recurrence
Researchers may have discovered a series of genes that will help predict whether or not a woman with hormone receptor-positive invasive breast cancer will experience early, late or no recurrence of her disease. [Press release from the American Association for Cancer Research discussing research presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio] Press Release

New Test Predicts Risk for Recurrence for Patients with DCIS
In a significant advance for patients with ductal carcinoma in situ (DCIS), researchers have developed and prospectively validated a multigene test to identify the risk for recurrence of breast cancer. [Press release from the American Association for Cancer Research discussing research presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio] Press Release

Clodronate Appeared Safe, Modestly Affected Breast Cancer Disease Events
A recently presented study revealed that the bisphosphonate clodronate had a low incidence of adverse events and toxicity among patients with breast cancer and may modestly reduce the incidence of distant metastases in postmenopausal women. [Press release from the American Association for Cancer Research discussing research presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio] Press Release

Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer
Researchers have proven the continuing effectiveness of treating patients with estrogen receptor (ER)-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression. [Press release from the American Association for Cancer Research discussing research presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio] Press Release

New Trials Show Land Mine Technology Can Give Women Fast, Accurate Breast Cancer Screening
A safe, low-cost system that would allow women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, has come a step closer following a third clinical trial. [University of Bristol] Press Release

AACR Board Member Named to President’s Cancer Panel
The American Association for Cancer Research (AACR) warmly congratulates Owen W. Witte, M.D. for being selected by President Obama to serve on the President’s Cancer Panel. [American Association for Cancer Research] Press Release

Institute of Medicine Released Report on Breast Cancer and the Environment
The report, sponsored by Susan G. Komen for the Cure, was released during a press briefing and presented at a plenary session at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. [American Association for Cancer Research] Press Release

American Society of Clinical Oncology Issues Annual Report on Progress Against Cancer
The American Society of Clinical Oncology (ASCO) released Clinical Cancer Advances 2011: ASCO’s Annual Report on Progress Against Cancer, an independent review of the advances in cancer research that have had the greatest impact on patient care this year. [American Society of Clinical Oncology]
Press Release 

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 3rd International Congress on Responsible Stem Cell Research
April 25-28, 2012
Vatican City, Rome

NEW American Association for Cancer Research – Molecularly Targeted Therapies: Mechanisms of Resistance
May 9-12, 2012
San Diego, United States

Visit our events page to see a complete list of events in the mammary cell community.

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Research Postdoctoral Fellow (Institut Curie UMR 144)

Postdoctoral Fellow (Thomas Jefferson University)

Postdoctoral Position for Translational Bioinformatics in Cancer Research (Baylor College of Medicine)

Postdoctoral Fellow (Tianjin Medical University Cancer Institute and Hospital)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.